Press coverage about iCo Therapeutics (OTCMKTS:ICOTF) has trended somewhat positive on Monday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. iCo Therapeutics earned a news impact score of 1.47 on their scale. InfoTrie also gave headlines about the biotechnology company an news buzz score of 10 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company’s share price in the near future.

OTCMKTS ICOTF remained flat at $$0.04 on Monday. 12,747 shares of the company traded hands, compared to its average volume of 670. The business’s 50-day moving average price is $0.04. iCo Therapeutics has a 12 month low of $0.03 and a 12 month high of $0.13.

About iCo Therapeutics

iCo Therapeutics Inc, a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat sight threatening ocular allergies and various systemic disease indications; and Oral AmpB Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections.

Further Reading: Technical Analysis of Stocks and What It Means

Receive News & Ratings for iCo Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for iCo Therapeutics and related companies with’s FREE daily email newsletter.

READ  What is Best Way to Conduct an ICO? Ethereum Founder Vitalik Buterin Weighs In